Italian observational study on T-DM1 in HER2 positive advanced breast cancer patients: real world effectiveness and safety

被引：0

作者：

Fabi, A. ^{[1
]}

Alesini, D. ^{[1
]}

De laurentiis, M. ^{[2
]}

Valle, E. ^{[3
]}

Santini, D. ^{[4
]}

Cannita, K. ^{[5
]}

Carbognin, L. ^{[6
]}

Ciccarese, M. ^{[7
]}

Arpino, G. ^{[8
]}

Leonardi, V. ^{[9
]}

Montemurro, F. ^{[10
]}

La Verde, N. ^{[11
]}

Generali, D. G. ^{[12
]}

Scandurra, G. ^{[13
]}

Russillo, M. ^{[14
]}

Paris, I. ^{[15
]}

D'Ottavio, A. M. ^{[16
]}

Filippelli, G. ^{[17
]}

Stani, S. ^{[18
]}

Giannarelli, D. ^{[1
]}

Cognetti, F. ^{[1
]}

机构：

[1] Ist Nazl Tumori Regina Elena, Rome, Italy

[2] Fdn Pascale, Ist Nazl Tumori, Naples, Italy

[3] Osped A Businco, Cagliari, Italy

[4] Campus Bio Med, Rome, Italy

[5] Presidio Osped S Salvatore, Laquila, Italy

[6] Azienda Univ Integrata Verona, Verona, Italy

[7] Osped Vito Fazzi, Lecce, Italy

[8] Univ Federico II, Naples, Italy

[9] ARNAS Civ, Palermo, Italy

[10] Fdn Piemonte Oncol, Candiolo, Italy

[11] Osped San Raffaele, Milan, Italy

[12] Ist Osped, Cremona, Italy

[13] Osped Oncol, Catania, Italy

[14] Osped Oncol, Lucca, Italy

[15] Univ Cattolica Sacro Cuore A Gemelli, Rome, Italy

[16] Osped S Giovanni Addolorata, Rome, Italy

[17] Osped S Francesco Paola, Paola, Italy

[18] Osped Santo Spirito, Rome, Italy

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷

关键词：

D O I：

10.1093/annonc/mdw337.7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

F07

引用

页数：1

共 50 条

[1] Real-life effectiveness of T-DM1 in heavily pretreated HER2-positive advanced breast cancer patients: An Italian observational study.
Fabi, Alessandra
Cannita, Katia
Ferretti, Gianluigi
Ciccarese, Mariangela
Arpino, Grazia
Montemurro, Filippo
La Verde, Nicla Maria
Generali, Daniele Giulio
Scandurra, Giuseppina
Filippelli, Gianfranco
Russillo, Michelangelo
Paris, Ida
Stani, Simonetta
Fabbri, Agnese
Minelli, Mauro
Cognetti, Francesco
Giannarelli, Diana
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[2] Safety and efficacy of T-DM1 in HER2 positive metastatic breast cancer patients: a real word experience
Omarini, C.
Medici, G.
Guaitoli, G.
Iattoni, E.
Moscetti, L.
Balduzzi, S.
Cascinu, S.
Piacentini, F.
ANNALS OF ONCOLOGY, 2016, 27
[3] T-DM1 for HER2 positive advanced breast cancer: a single institution, "real life" experience
Bertolini, I.
Ferrarini, I.
Fancelli, S.
De Angelis, C.
Fontana, A.
Salvadori, B.
Landucci, E.
Michelotti, A.
Falcone, A.
ANNALS OF ONCOLOGY, 2015, 26 : 20 - 21
[4] Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature
Martinez, Maria Teresa
Perez-Fidalgo, Jose Alejandro
Martin-Martorell, Paloma
Cejalvo, Juan Miguel
Pons, Vanesa
Bermejo, Begona
Martin, Miguel
Albanell, Joan
Lluch, Ana
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 97 : 96 - 106
[5] Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
Bon, Giulia
Pizzuti, Laura
Laquintana, Valentina
Loria, Rossella
Porru, Manuela
Marchio, Caterina
Krasniqi, Eriseld
Barba, Maddalena
Maugeri-Sacca, Marcello
Gamucci, Teresa
Berardi, Rossana
Livi, Lorenzo
Ficorella, Corrado
Natoli, Clara
Cortesi, Enrico
Generali, Daniele
La Verde, Nicla
Cassano, Alessandra
Bria, Emilio
Moscetti, Luca
Michelotti, Andrea
Adamo, Vincenzo
Zamagni, Claudio
Tonini, Giuseppe
Barchiesi, Giacomo
Mazzotta, Marco
Marinelli, Daniele
Tomao, Silverio
Marchetti, Paolo
Valerio, Maria Rosaria
Mirabelli, Rosanna
Russo, Antonio
Fabbri, Maria Agnese
D'Ostilio, Nicola
Veltri, Enzo
Corsi, Domenico
Garrone, Ornella
Paris, Ida
Sarobba, Giuseppina
Giotta, Francesco
Garufi, Carlo
Cazzaniga, Marina
Del Medico, Pietro
Roselli, Mario
Sanguineti, Giuseppe
Sperduti, Isabella
Sapino, Anna
De Maria, Ruggero
Leonetti, Carlo
Di Leo, Angelo
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2020, 39 (01)
[6] Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
Giulia Bon
Laura Pizzuti
Valentina Laquintana
Rossella Loria
Manuela Porru
Caterina Marchiò
Eriseld Krasniqi
Maddalena Barba
Marcello Maugeri-Saccà
Teresa Gamucci
Rossana Berardi
Lorenzo Livi
Corrado Ficorella
Clara Natoli
Enrico Cortesi
Daniele Generali
Nicla La Verde
Alessandra Cassano
Emilio Bria
Luca Moscetti
Andrea Michelotti
Vincenzo Adamo
Claudio Zamagni
Giuseppe Tonini
Giacomo Barchiesi
Marco Mazzotta
Daniele Marinelli
Silverio Tomao
Paolo Marchetti
Maria Rosaria Valerio
Rosanna Mirabelli
Antonio Russo
Maria Agnese Fabbri
Nicola D’Ostilio
Enzo Veltri
Domenico Corsi
Ornella Garrone
Ida Paris
Giuseppina Sarobba
Francesco Giotta
Carlo Garufi
Marina Cazzaniga
Pietro Del Medico
Mario Roselli
Giuseppe Sanguineti
Isabella Sperduti
Anna Sapino
Ruggero De Maria
Carlo Leonetti
Angelo Di Leo
Journal of Experimental & Clinical Cancer Research, 39
[7] Clinical efficacy and safety of T-DM1 for patients with HER2-positive breast cancer
Ma, Bo
Ma, Qianqian
Wang, Hongqiang
Zhang, Guolei
Zhang, Huiying
Wang, Xiaohong
ONCOTARGETS AND THERAPY, 2016, 9 : 959 - 976
[8] Trastuzumab emtansine (T-DM1) for HER2-positive advanced breast cancer
Thibault, C.
ONCOLOGIE, 2013, 15 (02) : 126 - 127
[9] Concomitant Association of T-DM1 and Radiation: An In Vitro Study on HER2 Positive Cells of Breast Cancer
Mignot, F.
Verrelle, P.
Kirova, Y.
Megnin-Chanet, F.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E186 - E186
[10] T-DM1 for HER2-positive metastatic breast cancer
Yaqub, Farhat
LANCET ONCOLOGY, 2013, 14 (03): : E94 - E94

← 1 2 3 4 5 →